What similarities do the serum tumor markers cancer antigen 125 (CA‑125) and cancer antigen 15‑3 (CA‑15‑3) have in assessing cancer risk in postmenopausal women?

Similarities Between CA 125 and CA 15-3 in Postmenopausal Cancer Risk Assessment

Both CA 125 and CA 15-3 are inadequate as standalone screening tests for cancer risk assessment in postmenopausal women due to insufficient sensitivity and specificity, though they share important characteristics as serum tumor markers that correlate with disease stage and can be elevated in multiple malignancies.

Shared Characteristics as Tumor Markers

Poor Screening Performance

Both markers demonstrate critical limitations for cancer risk assessment:

• CA 15-3 should not be used as a screening or diagnostic test because of low sensitivity 1
• CA 125 alone is inadequate when used in isolation as a screening tool, with only 50% of stage I ovarian cancer patients showing true-positive results 2

This shared limitation is particularly important in postmenopausal women, where false-positive CA 125 results are less common than in menstruating women (who have elevations from endometriosis, benign cysts, and pelvic inflammatory disease) 2.

Stage Correlation

Both markers show similar patterns of elevation correlating with disease burden:

• CA 15-3 concentrations correlate with breast cancer disease stage, with elevation rates of 5-30% (stage I), 15-50% (stage II), 60-70% (stage III), and 65-90% (stage IV) 3
• CA 125 demonstrates comparable stage-dependent sensitivity, with true-positive rates reaching 80% in stage II or greater ovarian cancer 2

Both markers are more often elevated in advanced versus localized disease 1.

Cross-Reactivity in Multiple Cancers

A critical similarity is that neither marker is cancer-specific:

• CA 15-3 can be elevated in ovarian cancer patients, with 57% showing elevations >30 U/mL 4
• CA 125 can be elevated in breast cancer and other malignancies including pancreatic cancer and cirrhosis 2

Research demonstrates that in ovarian cancer patients, CA 15-3 was elevated in 57% of cases, while in benign disease with elevated CA 125, CA 15-3 was elevated in only 2% 4. This cross-reactivity means both markers lack the specificity needed for cancer-type differentiation.

Improved Specificity Through Combination Testing

Both markers show enhanced performance when used together rather than individually:

Studies in postmenopausal women demonstrate that combining CA 125 with CA 15-3 (and TAG 72.3) increased specificity from 97.0% to 98.9% when defining a positive test as elevated CA 125 plus either CA 15-3 >30 U/mL or TAG 72.3 >10 U/mL 5. Among ovarian cancer patients with elevated CA 125, either TAG 72 or CA 15-3 was elevated in 77%, but in the false-positive benign disease group, only 6% had elevations of one or the other marker 4.

Influence of Menopausal Status

Both markers are affected by hormonal and demographic factors in postmenopausal women:

• CA 125 levels are significantly lower in postmenopausal versus premenopausal women 6
• CA 15-3 levels are significantly higher in postmenopausal women 6
• Advanced age is associated with higher CA 125 levels, while hormone replacement therapy and smoking correlate with lower levels 7
• Oral contraceptive use is associated with lower CA 15-3 levels 7

Clinical Implications for Postmenopausal Women

Not Recommended for Risk Assessment

Neither marker should be used for cancer risk assessment or screening in asymptomatic postmenopausal women 1, 2, 1, 3. The evidence is consistent across multiple guidelines that these markers lack sufficient sensitivity for early-stage disease detection.

Role Limited to Known Disease

Both markers are primarily useful for:

• Monitoring treatment response in established metastatic disease 1
• Detecting recurrence in patients with known cancer history (though early detection does not improve survival) 1
• Prognostic information correlating with disease stage 1

Common Pitfalls to Avoid

1. Do not use elevated levels to diagnose cancer type - both markers show cross-reactivity
2. Do not screen asymptomatic women - insufficient sensitivity and no mortality benefit demonstrated
3. Account for menopausal status when interpreting values, as reference ranges differ 6
4. Perform serial testing in the same laboratory using the same technique, as results are assay-dependent 1

The most recent guideline evidence (2018) reinforces that CA 125 has insufficient data to support routine use in ovarian cancer surveillance 8, and the 2003 guidelines remain the standard showing CA 15-3 should not be used for breast cancer screening 1.